Author

C. E. Rowland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Organism:E. coli· 1 Organism:human· 1

Frequent Co-Authors

A. J. Lloyd· 1 shared A. L. Richer· 1 shared C. G. Dowson· 1 shared C. Kessler· 1 shared C. S. Nesiba· 1 shared D. Bellini· 1 shared D. I. Roper· 1 shared E. S. Sokol· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. J. Lloyd

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Discovery and chemical optimisation of a Potent, Bi-cyclic (Bicycle(R)) Antimicrobial Inhibitor of Escherichia coli PBP3

C. E. Rowland, H. Newman, T. T. Martin, R. Dods, N. Bournakas, J. M. Wagstaff, N. Lewis, S. J. Stanway, M. Balmforth, C. Kessler, K. van Rietschoten, D. Bellini, D. I. Roper, A. J. Lloyd, C. G. Dowson, , M. J. Dawson

This study discovers and optimizes bicyclic peptide inhibitors of E. coli PBP3, showing high-affinity binding and broad-spectrum antimicrobial activity.

bioRxiv · Mar 20, 2024 · PreprintBiochemistry

Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast

J. L. Sottnik, M. T. Shackleford, C. S. Nesiba, A. L. Richer, Z. Fleischmann, J. M. Swartz, C. E. Rowland, M. Musick, R. Fu, L. R. Myler, P. L. Opresko, S. Mehrotra, E. S. Sokol, J. R. Hesselberth, J. R. Diamond, M. J. Sikora

This study identifies MDC1's role in ER co-regulation and DNA repair dysfunction in ILC, linking it to PARP inhibitor sensitivity.

bioRxiv · Oct 29, 2023Cancer Biology